Company
Who we are
What we do
Investor relations
News & key figures
Investor presentation
Xlife dates
ESG
Projects
Technology Platforms
Biotech and Therapies
Medical Technology
Artificial Intelligence
Contact
DE
Collaborative
Analyst coverage
Institute
Analyst
Target price
Report
Intron Health Research
Dominic Rose
47 CHF
view
Baader Bank
Amandeep Goyal
69.8 CHF
view
Stifel
Daniel Jelovcan
68 CHF
view
News
Press Releases
29.9.23
ESG Report shows status quo and outlines path for future sustainability improvements
20.6.23
Shareholders approved all motions at today’s AGM 2023
23.1.23
Stifel initiates research coverage of Xlife Sciences
Archive
Ad hoc News
18.10.2023
Successful exit of portfolio company and major invest in AI and digital health in early cancer detection, valued at CHF 23.3 million
21.9.2023
Xlife Sciences with significant progress in H1 2023
17.8.2023
Collaboration of Xlife Sciences and the Department of Health – Abu Dhabi to drive global innovations in the life sciences sector
Archive
Downloads
Financial Reports
September 21, 2023
Half-Year Report 2023
April 27, 2023
Valuation Report 2022
April 20, 2023
Annual Report 2022
September 28, 2022
Half-Year Report 2022
May 9, 2022
Valuation Report 2021
April 29, 2022
Annual Report 2021
February 8, 2022
Interim financial statement Q3 2021 (only in german)
August 5, 2021
Semi-Annual Report 2021
Half-year results (only available in German)
May 29, 2020
Annual statement 2020
Sign up for our media releases